April 1, 2021
FDA approves Sanofi’s Sarclisa to treat relapsed multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
March 15, 2021
Sanofi, Regeneron post positive results in P3 testing of Libtayo (oncology) monotherapy
Sanofi and Regeneron posted positive results with an overall survival (OS) benefit from the Phase 3 trial investigating its PD-1 inhibitor Libtayo (cemiplimab) monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
June 16, 2020
Sanofi invests in vaccine production in France, €490 million over five-years
Sanofi on Tuesday detailed plans investing in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks, aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.
June 12, 2020
Denali and Sanofi pause studies with DNL747 in Alzheimer’s and ALS (edited)
Denali Therapeutics and Sanofi have paused clinical studies with small molecule RIPK1 inhibitor DNL747 in Alzheimer’s disease and ALS, due to emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and certain challenges.
June 1, 2020
Dupixent meets primary and key secondary endpoints in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi have shared positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE), in which the trial met both co-primary endpoints.
May 29, 2020
Sanofi highlights significant long-term outcomes with Libtayo
Sanofi said Friday that Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time.
May 29, 2020
Mylan invalidates Sanofi’s Lantus SoloSTAR device patents in IPR proceedings
Mylan said on Friday that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi’s Lantus® SoloSTAR® device patents, U.S. Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable.
May 23, 2020
Sanofi, Regeneron’s Dupixent trial meets both co-primary endpoints
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
May 12, 2020
Sanofi’s p3 trial of Sarclisa showed promising results with myeloma patients
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
May 7, 2020
Schreiner MediPharm makes booklet-label for Sanofi’s clinical trial
Schreiner MediPharm has developed a compact Booklet-Label for a needle protection system used in an international phase III clinical trial conducted by pharmaceutical corporation Sanofi.